In the News

Gov. Scott Lifts All Remaining COVID-19 Restrictions in Vermont – VPR

Read article – Peter Wright, professor of pediatrics, is quoted in an article reporting that Vermont is lifting remaining COVID-19 pandemic restrictions. Asked for advice on what parents should do if their children aren’t old enough to get vaccinated, Wright said, “It just becomes a matter of your own assessment of the risk you want to take for your child … You’re really trying to think about the whole umbrella you’re under.”

Study Shows How Cowpea Mosaic Plant Virus Stimulates the Immune System Against Cancer – News Medical

Read article – A study co-authored by Steven N. Fiering, professor of microbiology and immunology, and researcher at Norris Cotton Cancer Center, finds that cowpea mosaic plant virus (CPMV) stimulates the immune system to attack and often eliminate a cancerous tumor. “The recognition of CPMV by toll-like receptors illustrates how these receptors are quite flexible and recognize many more molecular patterns than immunologists previously knew,” said Fiering.

DIY Nerve Stimulation Device ‘Highly Effective’ for Migraine Pain – Medscape

Read article – Stewart Tepper, professor of neurology, is quoted about a noninvasive, self-administered neurostimulation device to treat migraine pain. “This multicenter, pivotal, regulatory, sham-controlled study provides evidence that self-administered, noninvasive, combined occipital and trigeminal neurostimulation is a safe and highly effective acute treatment for migraine,” said Tepper.

Low-Value End-of-Life Care in Some Patients With Cancer – Medscape

Read article – Maxwell Thomas Vergo, associate professor of medicine, is quoted about a study examining end-of-life care for patients with metastatic cancer who belong to racial and ethnic minority groups or have Medicare or Medicaid coverage. Vergo said, “Most studies look at end-of-life care in the last 30 days of life, but they don’t really include what the last days or hours of life look like, which can be tremendously important.”

Low Migraine Recurrence With Intranasal DHE – MedPage Today

Read article – Stewart Tepper, professor of neurology, is quoted about research presented at the American Headache Society virtual meeting on the use of Intranasal INP104, dihydroergotamine mesylate (DHE) as a treatment for migraines. “One of the most useful features of DHE is that it tends to give a complete acute migraine treatment, that is, a pain-free response without return of headache and without need for retreatment or rescue medication — a one-and-done outcome,” said Tepper.